Tela Bio, Inc. · NASDAQ:TELA
Tela Bio — Investor Presentation (August 2024)
19 slides from Tela Bio's investor presentation, Aug 12, 2024
Slide 1: Investor Presentation August 2024
INVESTOR PRESENTATION August 2024
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possi
Slide 3: TELA Bio, Inc.
TELA Bio, Inc. • Advanced reinforced tissue matrix portfolio supported by compelling clinical evidence • $2.2B US market opportunity 1 – still in early stages of growth • Driving commercial adoption with targeted direct - sales approach • Recent product launches in growing markets: robotic hernia su
Slide 4: Science. Value. Innovation.
@TELABIO SCIENCE. VALUE. INNOVATION.
Slide 5: U.S. Hernia Surgery Market: ~$1.5 Billion Annual Opportunity
Complex, Moderate Ventral / Abdominal Wall Reconstruction Simple Ventral Hernia Repair Inguinal Hernia Repair Hiatal Hernia Repair ~60,000 ~345,000 ~665,000 ~40,000 $360M $515M $600M $40M 1 Sources: Millennium Research Group Reports, IMS Health Data; iData Research MedSKU 2 Management estimate. Mark
Slide 6: OviTex product family
OviTex Core 4 - layer device No smooth sides Robot Compatible 1 : Yes OviTex Core is designed to reinforce primary hernia repairs where the device will not come into contact with viscera . OviTex 1S 6 - layer device 1 smooth side Robot Compatible 1 : Yes OviTex 1S incorporates a smooth side that is
Slide 7: Need for Alternative to Permanent Synthetic Mesh
Lawsuits against permanent synthetic meshes estimated to be assembled across the U.S. 3 of surgeons agree that use of permanent synthetic mesh puts patients at long - term risk of complications 1 1. Hernia and Abdominal Surgeries Survey (Oct 2020). A group of 71 surgeons were surveyed regarding use
Slide 8: OviTex clinical results by procedure type
Ankney , Szotek et al. – 2021 4 * 54 patients Follow - up 3 - 38 months Ferzoco – 2018 3 * 31 patients Average follow up 13 months INGUINAL 0% Ankney , Szotek et al. – 2021 4 * 306 patients Follow up 1 - 36 months INGUINAL 1.6% Sawyer – 2018 1 * 25 patients Average follow up 14 months HIATAL 0% DeNo
Slide 9: Favorable Results of OviTex in Ventral Hernia Repair
Parker et al. 8 Sivaraj et al. 5 Total enrolled patients 50 OviTex 50 Polypropylene 36 OviTex 51 Strattice 17 Permacol 37 Surgimend Length of follow - up 12 months 12 months 28.6 months (median) 34.6 months (median) 58.4 months (median) 37.5 months (median) mVHWG 32% grade 2 68% grade 3 a 94% grade
Slide 10: Positive 24-month BRAVO results in ventral hernia
* Kaplan - Meier survival estimate **No head - to - head clinical studies have been conducted. Due to differences in patient population, surgeons, surgical technique, and other variables, no direct comparisons of results can be made. For a comparative discussion of these studies, please see G. DeNot
Slide 11: Hernia Market Evolution
2027 2021 2018 2013 Permanent Synthetic Biologic Resorbable Synthetics Reinforced Tissue Matrix Sources for Sales Market Share (%): 2009 - 2013 = IMS Hospital Supply Index; 2018 - 2021 = iData Research MedSKU ; 2027 = Management Estimate Sources for Total US Market Size: 2021 - 2027 = DRG Hernia Rep
Slide 12: Reinforced Tissue Matrix
VITHX Pi REINFORCED TISSUE MATRIX @TELABIO SCIENCE. VALUE. INNOVATION.
Slide 13: U.S. Plastic and Reconstructive Surgery Market: ~$700 Million Annual Opportunity
U.S. Plastic and Reconstructive Surgery Market: ~$700 Million Annual Opportunity Surgeons use products to reinforce soft tissue during various reconstructive surgeries 1 , including: ▫ Head and neck surgery ▫ Chest wall reconstruction ▫ Pelvic reconstruction ▫ Extremities reconstruction ▫ Breast rec
Slide 14: OviTex PRS: Specifically Designed for Plastic and Reconstructive Surgery
OviTex PRS: Specifically Designed for Plastic and Reconstructive Surgery An innovative reinforced tissue matrix designed to improve outcomes by facilitating fluid management and controlling degree and direction of stretch Product Features: ▫ Layers composed of biologic building block retain biologic
Slide 15: Leading-edge atraumatic hernia mesh fixation devices
Leading - edge atraumatic hernia mesh fixation devices
Slide 16: LIQUIFIX FIX8 and LIQUIFIX Precision
LIQUIFIX FIX8 Œ and LIQUIFIX Precision Œ Atraumatic liquid fixation device s • Reduce the need for penetrating mechanical fixation for inguinal and femoral hernia repair • Provide p rec ise , controlled adhesive application Fills an unmet need in the market, less damage to tissue • D esigned to mini
Slide 17: TELA Bio is growing each factor that contributes to sales
TELA Bio is growing each factor that contributes to sales, providing for multi - year, long - term growth 2021: 40 - 45 reps / 5 TB Ltd. 2022: 61 reps / 6 TB Ltd. 2023: 86 reps / 9 TB Ltd. 2Q24: 86 reps + 6 asst. reps / 9 TB Ltd. Driving Revenue Growth Rep Productivity Sales Force Size Product Portf
Slide 18: Delivering Revenue Growth and Margin Improvement
Delivering Revenue Growth and Margin Improvement Q2 2024 Performance ▫ Revenue of $ 16.1M grows 11 % over corresponding period of 2023 ▫ 69% Gross Margin ▫ Cash and Cash Equivalents at June 30 , 2024: $26.5M
Slide 19: Clinical References
CLINICAL REFERENCES 1. Sawyer, M.A.J. New Ovine Polymer - Reinforced Bioscaffold in Hiatal Hernia Repair. Jsls J Soc Laparoendosc Surg 2018, 22, e2018.00057, doi:10.4293/jsls.2018.00057. 2. DeNoto, G. Bridged Repair of Large Ventral Hernia Defects Using an Ovine Reinforced Biologic: A Case Series. A